JY0691, a newly synthesized obovatol derivative, inhibits cell cycle progression of rat aortic smooth muscle cells through up-regulation of p21cip1

European Journal of Pharmacology

Volumn 624, Issue 1-3, 2009, Pages 23-30

  Yu, Ji Yeon ^a   Lee, Jung Jin ^b   Jung, Jae Kyung ^c   Kim, Tack Joong ^d   Yoo, Hwan Soo ^c   Yun, Yeo Pyo ^c   Lee, Jeong Chae ^a  

^a Chonbuk National University   (South Korea)

^b Chungnam National University   (South Korea)

^c Chungbuk National University   (South Korea)

^d Yonsei University Wonju   (South Korea)

Author keywords

Cell cycle arrest; Obovatol derivative; p21cip1; Platelet derived growth factor; Rat aortic smooth muscle cell

Indexed keywords

3 (4 PROPYLPHENOXY) 4,5 DIHYDROXYBENZOIC ACID METHYL ESTER; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; CYCLINE; DIGITONIN; JY 0691; PHENOL DERIVATIVE; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; AORTA MEDIA; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UPREGULATION;

ANIMALS; AORTA; BIPHENYL COMPOUNDS; CELL CYCLE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; MYOCYTES, SMOOTH MUSCLE; PHENYL ETHERS; RATS; TIME FACTORS; UP-REGULATION;

EID: 70350738330     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.09.061     Document Type: Article

References (44)

1. Akiyama T., Ohuchi T., Sumida S., Matsumoto K., and Toyoshima K. Phosphorylation of the retinoblastoma protein by cdk2. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 7900-7904
2. Blenis J. Signal transduction via the MAP kinases: proceed at your own RSK. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 5889-5892
3. Bornfeldt K.E., Raines E.W., Graves L.M., Skinner M.P., Krebs E.G., and Ross R. Platelet-derivated growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Ann. N.Y. Acad. Sci. 766 (1995) 416-430
4. Braun-Dullaeus R.C., Mann M.J., Sedding D.G., Sherwood S.W., Von der leyen H.E., and Dzau V.J. Cell cycle-dependent regulation of smooth muscle cell activation. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 845-850
5. Brooks E.E., Gray N.S., Joly A., Kerwar S.S., Lum R., Mackman R.L., et al. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J. Biol. Chem. 272 (1997) 29207-29211
6. Chamley J.H., Campbell G.R., McConnell J.D., and Groschel-Stewart U. Comparison of vascular smooth muscle cells from adult human, monkey and rabbit in primary culture and in subculture. Cell Tissue Res. 177 (1997) 503-522
7. Claesson-Welsh L. Platelet-derived growth factor receptor signals. J. Biol. Chem. 269 (1994) 32023-32026
8. Collins K., Jacks T., and Pavletich N.P. The cell cycle and cancer. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 2776-2778
9. Connell-Crowley L., Elledge S.J., and Harper J.W. G1 cyclin-dependent kinases are sufficient to initiate DNA synthesis in quiescent human fibroblasts. Curr. Biol. 8 (1998) 65-68
10. Conqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function of each cell compartment?. Trends Cell Biol. 13 (2003) 65-70
11. Conqueret O. New targets for viral cyclins. Cell Cycle 2 (2003) 293-295
12. Dzau V.J., Braun-Dullaeus R.C., and Sedding D.G. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. 8 (2002) 1249-1256
13. Jack T., and Weinberg R.A. Cell-cycle control and its watchman. Nature 381 (1996) 643-644
14. Jirawatnotai S., Aziyu A., Osmundson E.C., Moons D.S., Zou X., Kineman R.D., and Kiyokawa H. Cdk4 is indispensable for postnatal proliferation of the anterior pituitary. J. Biol. Chem. 279 (2004) 51100-51106
15. Kim J.H., Jin Y.R., Park B.S., Kim T.J., Kim S.Y., Lim Y., Hong J.T., Yoo H.S., and Yun Y.P. Luteolin prevents PDGF-BB-induced proliferation of vascular smooth muscle cells by inhibition of PDGF beta-receptor phosphorylation. Biochem. Pharmacol. 69 (2005) 1715-1721
16. Kim H.J., Yoo E.K., Kim J.Y., Choi Y.K., Lee H.J., Kim J.K., Jeoung N.H., Lee K.U., Park I.S., Min B.H., Park K.G., Lee C.H., Aronow B.J., Sata M., and Lee I.K. Protective role of clusterin/apolipoprotein J against neointimal hyperplasia via antiproliferative effect on vascular smooth muscle cells and cytoprotective effect on endothelial cells. Arterioscler. Thromb. Vasc. Biol. 29 (2009) 1558-1564
17. Kim T.J., Han H.J., Lim Y., Song M.C., Kim J., Hong J.T., Yoo H.S., Pyo M.Y., Hwang B.Y., Lee M.K., and Yun Y.P. Antiproliferative action of cudraflavone B, isolated from Cudrania tricuspidata, through the downregulation of pRb phosphorylation in aortic smooth muscle cell proliferation signaling. J. Cardiovasc. Pharmacol. 53 (2009) 341-348
18. Lee M.S., Yang J.E., Choi E.H., In J.K., Lee S.Y., Lee H., Hong J.T., Lee H.Y., Suh Y.G., and Jung J.K. Synthesis of obovatol derivatives and their preliminary evaluation as antitumor agents. Bull. Korean Chem. Soc. 28 (2007) 1601-1604
19. Lee S.K., Kim H.N., Kang Y.R., Lee C.W., Kim H.M., Han D.C., Shin J., Bae K., and Kwon B.M. Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis. Bioorg. Med. Chem. 16 (2008) 8397-8402
20. Lee S.Y., Yuk D.Y., Song H.S., Yoon d.Y., Jung J.K., Moon D.C., Lee B.S., and Hong J.T. Growth inhibitory effects of obovatol through induction of apoptotic cell death in prostate and colon cancer by blocking of NF-kappaB. Eur. J. Pharmacol. 582 (2008) 17-25
21. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
22. Lipson K.E., Pang L., Huber L.J., Chen H., Tsai J.M., Hirth P., et al. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation. J. Pharmacol. Exp. Ther. 28 (1998) 844-852
23. Macleod K.F., Sherry N., Hannon G., Beach D., Tokino T., Kinzler K., et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9 (1995) 935-944
24. Majesky M.W., Reidy M.A., Bowen-Pope D.F., Hart C.E., Wilcox J.N., and Schwartz S.M. PDGF ligand and receptor gene expression during repair of arterial injury. J. Cell Biol. 111 (1990) 2149-2158
25. Marra D.E., Simoncini T., and Liao J.K. Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1). Circulation 102 (2000) 2124-2130
26. Martin A., Odajima J., Hunt S.L., Dubus P., Ortega S., Malumbres M., and Barbacid M. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 7 (2005) 591-598
27. Mulvany M.J. Structure and function of small arteries in hypertension. J. Hypertens. Suppl. 8 (1990) 225-232
28. Myllarniemi M., Frosen J., Calderon Ramirez L.G., Buchdunger E., Lemstrom K., and Hayry P. Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovasc. Drugs Ther. 13 (1999) 159-168
29. Norbury C.J., and Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 23 (2004) 2797-2808
30. Orgeta S., Malumbers M., and Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta 1602 (2002) 73-87
31. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
32. Ross R. Cell biology of atherosclerosis. Annu. Rev. Physiol. 57 (1995) 791-804
33. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
34. Sachinidis A., Locher R., Vetter W., Tatje D., and Hoppe J. Different effects of platelet-derived growth factor isoforms on rat vascular smooth muscle cells. J. Biol. Chem. 265 (1990) 10238-10243
35. Sasaguri T., Ishida A., Kosaka C., Nojima H., and Orgeta J. Phorbol ester inhibits the phosphorylation of the retinoblastoma protein without suppressing cyclin D-associated kinase in vascular smooth muscle cells. J. Biol. Chem. 271 (1996) 8345-8351
36. Schwartz R.S., Holmes Jr. D.R., and Topol E.J. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J. Am. Coll. Cardiol. 20 (1992) 1284-1293
37. Sherr C.J. Cancer cell cycles. Science 274 (1996) 1672-1677
38. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60 (2000) 3689-3695
39. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13 (1999) 1501-1512
40. Strauss B.H., Chisholm R.J., Keeley F.W., Gotlieb A.I., Logan R.A., and Armstrong P.W. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ Res. 75 (1994) 650-658
41. Tanner F.C., Boehm M.L., Akyürek L.M., San H., Yang Z.Y., Tashiro J., Nabel G.J., and Nabel E.G. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smoothmuscle cell proliferation. Circulation 101 (2000) 2022-2025
42. Tomita H., Osanai T., Toki T., Maeda N., Murakami R., Chen Z., Yamabe H., Osawa H., Yasujima M., and Okumura K. Roxithromycin is an inhibitor of human coronary artery smooth muscle cells proliferation: a potential ability to prevent coronary heart disease. Atherosclerosis 182 (2005) 87-95
43. Waltenberger J. Modulation of growth factor action: implications for the treatment of cardiovascular diseases. Circulation 96 (1997) 4083-4094
44. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., and Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366 (1993) 701-704